Investigation of genome-wide SNP analysis and its significance in KYUCOG-1401 (randomized controlled study of GnRH antagonist monotherapy and CAB with GnRH agonist plus bicartamide for patients with metastatic prostate cancer).

Investigation of genome-wide SNP analysis and its significance in KYUCOG-1401 (randomized controlled study of GnRH antagonist monotherapy and CAB with GnRH agonist plus bicartamide for patients with metastatic prostate cancer). - KYUCOG-1401 ancillary study (KYUCOG-1401-A)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022852

Enrollment

200

Registered

2016-06-23

Start date

2016-06-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) Patients enrolled in KYUCOG-1401 study (UMIN000014243) (2) Patients with written informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients in the ethnic group or the race except the Japanese (2) Any other patients who are regarded as unsuitable for this study by the investigators.

Design outcomes

Primary

Measure	Time frame
Genome-wide SNP analysis using Japonica array.	—

Secondary

Measure	Time frame
Correlation between SNP information and clinical information (subject characteristics, clinical laboratory test, imaging test and endpoints) in KYUCOG-1401.	—

Countries

Japan

Contacts

Public ContactMasaki Shiota

Kyushu University Graduate School of Medicine Department of Urology

shiota@uro.med.kyushu-u.ac.jp092-642-5603

Outcome results